Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 52 min ago
Peer-reviewedCC BY 4.0Nutrients

Limosilactobacillus reuteri DSM 17938 Attenuates Hyperoxia-Induced Lung Injury in a Newborn Rat Model

  1. 1Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of Korea
  2. 2Cell and Gene Therapy Institute, Samsung Medical Center, Seoul 06351, Republic of Korea
  3. 3Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan University, Seoul 06351, Republic of Korea

Abstract

Background/Objectives: Bronchopulmonary dysplasia (BPD) remains a leading cause of morbidity in preterm infants, and effective preventive strategies are lacking. This study investigated the protective effect of orally administered Limosilactobacillus reuteri DSM 17938 in a neonatal rat model of hyperoxia-induced lung injury. Methods: Newborn Sprague-Dawley rat pups were randomly allocated to normoxia control (NC), hyperoxia control (HC), and hyperoxia with probiotic supplementation (HP) groups. The HC and HP groups were exposed to 90% oxygen from postnatal day 1 to 14. L. reuteri DSM 17938 (3.3 × 104 CFU/day) was administered orally from postnatal day 3. Pulmonary outcomes were assessed by histological analyses including mean alveolar volume, radial alveolar count, von Willebrand factor immunofluorescence staining, and TUNEL assay. Gut and pulmonary microbiome composition was evaluated by 16S rRNA sequencing, and intestinal butyrate and glutathione levels were measured. Results: Probiotic supplementation significantly improved alveolarization and pulmonary vascular endothelial marker expression, with a concurrent reduction in apoptotic cell death and ED1-positive cell accumulation compared with the HC group (all p < 0.05). Hyperoxia-induced phylum-level shifts in Firmicutes and Bacteroidetes abundance were partially attenuated in the HP group, although alpha- and beta-diversity indices and genus- and species-level analyses did not show a consistent pattern of restoration. Intestinal butyrate and glutathione levels were significantly lower in the HC group than in the NC group (p < 0.05). Concentrations in the HP group were numerically higher than in the HC group but did not differ significantly from either the NC or HC group. In lung tissue, SOD2 gene expression was significantly increased in the HP group compared with both the NC and HC groups (p < 0.05). Conclusions: Oral L. reuteri DSM 17938 attenuates hyperoxia-induced lung injury in a neonatal rat model, with increased pulmonary SOD2 gene expression, alongside a consistent directional trend in related antioxidant pathway genes, and phylum-level gut microbiome changes identified as potential contributing mechanisms. These findings provide preclinical evidence for a potential protective effect of this commercially available probiotic strain against hyperoxia-induced lung injury, warranting further investigation before translation to clinical prevention strategies for BPD.

Related

  1. Bovine milk-derived osteopontin attenuates hyperoxia-induced lung injury associated with NLRP3 inflammasome regulation in neonatal mice with bronchopulmonary dysplasia
    Translational pediatricsPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  2. Limosilactobacillus reuteri for oral mucositis in patients undergoing radiotherapy for malignant head and neck tumors: a randomized controlled trial.
    Kun Gao, Yuan-Tai Li, Yi-Yan Pei +10
    Nature communicationsPeer-reviewedCC BYFull textGeneral medicineEurope PMCPMC
  3. Efficacy of a Limosilactobacillus reuteri DSM 17938 and BG-R46® Formulation in Predominantly Breastfed Infants with Infant Distress Syndrome: A Randomized Double-Blind Placebo-Controlled Trial
    Flavia Indrio, Luca Pecoraro, Pierluigi Manni +2
    NutrientsPeer-reviewedCC BY 4.0NutritionCrossref
  4. Efficacy and safety of Limosilactobacillus reuteri DSM 17938 for the treatment of acute gastroenteritis in children: a systematic review and meta-analysis of randomized controlled trials
    Ener Cagri Dinleyici, Flavia Indrio, Pedro Gutierrez-Castrellon +1
    Frontiers in pediatricsPeer-reviewedCC BYFull textGeneral medicineEurope PMCPMC
  5. Limosilactobacillus reuteri ameliorates diet-associated metabolic dysfunction in PCOS-like rats: associations with intestinal lipid remodeling and GPR120-related regulation
    Cong Wang, Cong Wang, Shang Li +23
    Frontiers in NutritionPeer-reviewedCC BYFull textNutritionDOAJ
BibTeX
@article{kim2026limosilactobacillus,
  title = {{Limosilactobacillus reuteri DSM 17938 Attenuates Hyperoxia-Induced Lung Injury in a Newborn Rat Model}},
  author = {Seung Hyun Kim and Young Eun Kim and Dong Kyung Sung and Misun Yang and Se In Sung and Yun Sil Chang and So Yoon Ahn},
  journal = {Nutrients},
  year = {2026},
  month = oct,
  doi = {10.3390/nu18203328},
  url = {https://www.mdpi.com/2072-6643/18/20/3328},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Limosilactobacillus reuteri DSM 17938 Attenuates Hyperoxia-Induced Lung Injury in a Newborn Rat Model
AU  - Seung Hyun Kim
AU  - Young Eun Kim
AU  - Dong Kyung Sung
AU  - Misun Yang
AU  - Se In Sung
AU  - Yun Sil Chang
AU  - So Yoon Ahn
PY  - 2026
DA  - 2026/10/01
JO  - Nutrients
DO  - 10.3390/nu18203328
UR  - https://www.mdpi.com/2072-6643/18/20/3328
AB  - Background/Objectives: Bronchopulmonary dysplasia (BPD) remains a leading cause of morbidity in preterm infants, and effective preventive strategies are lacking. This study investigated the protective effect of orally administered Limosilactobacillus reuteri DSM 17938 in a neonatal rat model of hyperoxia-induced lung injury. Methods: Newborn Sprague-Dawley rat pups were randomly allocated to normoxia control (NC), hyperoxia control (HC), and hyperoxia with probiotic supplementation (HP) groups. The HC and HP groups were exposed to 90% oxygen from postnatal day 1 to 14. L. reuteri DSM 17938 (3.3 × 104 CFU/day) was administered orally from postnatal day 3. Pulmonary outcomes were assessed by histological analyses including mean alveolar volume, radial alveolar count, von Willebrand factor immunofluorescence staining, and TUNEL assay. Gut and pulmonary microbiome composition was evaluated by 16S rRNA sequencing, and intestinal butyrate and glutathione levels were measured. Results: Probiotic supplementation significantly improved alveolarization and pulmonary vascular endothelial marker expression, with a concurrent reduction in apoptotic cell death and ED1-positive cell accumulation compared with the HC group (all p < 0.05). Hyperoxia-induced phylum-level shifts in Firmicutes and Bacteroidetes abundance were partially attenuated in the HP group, although alpha- and beta-diversity indices and genus- and species-level analyses did not show a consistent pattern of restoration. Intestinal butyrate and glutathione levels were significantly lower in the HC group than in the NC group (p < 0.05). Concentrations in the HP group were numerically higher than in the HC group but did not differ significantly from either the NC or HC group. In lung tissue, SOD2 gene expression was significantly increased in the HP group compared with both the NC and HC groups (p < 0.05). Conclusions: Oral L. reuteri DSM 17938 attenuates hyperoxia-induced lung injury in a neonatal rat model, with increased pulmonary SOD2 gene expression, alongside a consistent directional trend in related antioxidant pathway genes, and phylum-level gut microbiome changes identified as potential contributing mechanisms. These findings provide preclinical evidence for a potential protective effect of this commercially available probiotic strain against hyperoxia-induced lung injury, warranting further investigation before translation to clinical prevention strategies for BPD.
SN  - 2072-6643
ER  -